FDA buoys Pozen, accepts of amended response

Shares of Pozen rallied 16 percent on news that the FDA had accepted its amended response for the experimental migraine drug Trexima. The amendment was filed in February after Trexima was rejected in December. Pozen has been working with GlaxoSmithKline to gain an approval on Trexima, a combination of Glaxo's Imitrex and the anti-inflammatory naproxen.

- read Pozen's release
- here's the report from LocalTechWire

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.